Ipamorelin Side Effects: Safety Signals and Warnings
Ipamorelin safety concerns are compound-specific. The main listed side effects are Headache (most common), Water retention, and Numbness or tingling in extremities. The main warning signals are Not FDA-approved for any indication, May affect glucose metabolism, and Caution in individuals with active cancer.
Direct Answer
Ipamorelin stands out among growth hormone secretagogues for one critical reason: it is the only GHRP that does not significantly elevate cortisol, ACTH, or prolactin at research doses. This selectivity makes it the cleanest tool for studying GH pulsatility in isolation. It has Phase 2 human data (post-operative ileus trial) confirming pharmacological activity. The body composition effects are real but modest - ipamorelin is not a substitute for exogenous GH, it is a physiologically cleaner way to study GH secretion.
- Evidence grade
- Level B
- Research status
- Phase 2
- Category
- Growth Hormone
- Best for
- GH secretagogue research, clean GH pulsatility, stacking with GHRH analogs
Reported Side Effects
- Headache (most common)
- Water retention
- Numbness or tingling in extremities
- Possible increased hunger
- Lightheadedness
Warnings
- Not FDA-approved for any indication
- May affect glucose metabolism
- Caution in individuals with active cancer
- May interact with the hypothalamic-pituitary axis
- Banned by WADA in competitive sports
Known or Plausible Interactions
- Exogenous growth hormone (additive effects)
- Insulin (may affect insulin sensitivity)
- Glucocorticoids (may blunt GH response)
- Other GHRPs and GHRH analogs (synergistic)
Regulatory Context
Ipamorelin is not FDA-approved and is classified as a research peptide. Banned by WADA in competitive sports. Available for research purposes in most jurisdictions. Not a controlled substance but cannot be marketed for human consumption.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Phase 2 |
| Best supported outcomes | Growth Hormone Release (Level B), Body Composition (Level C), Bone Density (Level C), and Sleep Quality (Level C) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Ipamorelin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/ipamorelin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.